Safety and efficacy of strontium-89 for prostate cancer with painful bone metastases in Japanese patients
Not Applicable
Recruiting
- Conditions
- castration-resistant prostate cancer patients with painful bone metastases
- Registration Number
- JPRN-UMIN000004517
- Lead Sponsor
- Yokohama City Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Male
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
(1) Severe myelosuppression *Severe myelosuppression should be measured by hematologic functions (platelets < 50,000/mm3, WBC < 2,000/mm3, neutrophils < 1,000/mm3, Hb < 8.0/dL). (2) Diagnosis of disseminated intravascular coagulation syndrome (DIC) (3) Severe renal dysfunction (e.g. renal failure of NCI Common Toxicity Criteria Grade 3/4)
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method